“This study really demonstrates, for one of the first times certainly in the largest cohort of men ever [studied], that Rezum water vapor thermal therapy is a viable option to treat men with very large prostates bigger than 80 mL,” says Dean Elterman, MD, MSc, FRCSC.
“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.
“I want to reiterate that this study doesn't necessarily say that 1 approach is better than the other, but it definitely does reinforce some advantages of robotic surgery that have been shown not just in this study, but in other studies as well,” says Peter Chang, MD, PhD.
“[We gave the ES kits out] with the idea that instead of having these people…travel…hundreds of miles to a main hospital for their endoscopy, the urologist could travel to a village with just the smartphone and the endoscope set-up and proceed to do a ton of endoscopy there,” says Ralph V. Clayman, MD.
"This work isn't for one; it is certainly for all,” says Efe C. Ghanney Simons, MD.
“Rather than asking the staff to have a stiff upper lip and cope, we instead tried to focus on uncovering systemic processes that were ripe for change,” says Loren Jean Smith.
“The quality of life overall between the 2 approaches was very similar,” says Peter Chang, MD, PhD.
“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.
“I think the key [is to not] get rid of financial incentives. I don't think that's possible. [Rather, we should] align financial incentives [so] that [we] can promote what is best for patients,” says Lillian Y. Lai, MD.
“The goal of this research endeavor was to really set forth the background information that would guide the creation of targeted interventions,” says Efe C. Ghanney Simons, MD.
Welcome to the first installment of Uranimals, a video series featuring urologists and their pets brought to you by Urology Times. From a dog model to a whole farm of animals, the inaugural episode has an amazing lineup.
“[BPH treatment] has to be individualized to the motivations of the patient, and also what I call his "phenotype.” How big is his prostate? How bad is this problem? And what is his tolerance for side effects?” says Kevin T. McVary, MD.
“More research needs to be done, but I think this is something that gets the conversation started,” says Tony Chen, MD.
“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.
“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.
“I think the real driving factor in all of this is that collecting smoking status and tobacco use is hard. It's difficult to get this information out. It requires a lot of time; it requires energy; it requires infrastructure in the data and the electronic medical record,” says Richard Matulewicz, MD, MS.
“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.
“My patient selection process for BPH treatments can be a little bit cumbersome and take time, but that's really because for the first time ever, we have so many different options available to men,” says Dean Elterman, MD, MSc, FRCSC.
“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.
“The most important takeaway is really good preoperative counseling. Patients should not expect surgeries to be pain free,” says Sarah F. Faris, MD.
“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.
“Tramadol is a mixed-class medication and it has weak opioid agonist activity. Normally, we consider that a safer option compared to other opioids, but it's actually a pro drug, so it has to be metabolized to have an effect,” says Sarah F. Faris, MD.
“It was nice to use the military health system to look at the population, which tends to be very diverse…[It allowed] us to get pretty large numbers to make some better conclusions about what’s already been established in this population,” says David A. Klein, MD, MPH.
Get ready for the 2021 AUA annual meeting with this preview of non-malignant topics.
“We have to be really careful prescribing tramadol and be aware that [it] can have really variable effects for patients,” says Sarah F. Faris, MD.
“Through these 2 small punctures, we can manipulate the device with the methodology to sample the entire prostate, both anterior apical and the posterior regions, where we find the vast majority of our cancers,” says Matthew A. Allaway, MD.
“Appropriately selecting your patient will result in a successful telehealth visit,” says Nitya E. Abraham, MD.
“The transperineal [prostate biopsy] approach is safer because the needles are passed through the perineal skin…so, we can sterilize that skin and if we enter through that passageway, we mitigate, if not eliminate, the risk of infection and sepsis,” says Matthew J. Allaway, MD.
“Transgender and gender-diverse people are at a higher risk of a multitude of mental health diagnoses, [which] really lends itself to a sensitive psycho-social history regardless of the specialty,” says David A. Klein, MD, MPH.
“The 3 major barriers we face [are] training, equipment, and reimbursement,” says Matthew A. Allaway, MD.
